Company Encyclopedia
View More
name
Vident International Equity Strategy ETF
VIDI.US
News
View More

Dir O'Keefe Surrenders 603 Of Jazz Pharmaceuticals Plc [JAZZ]

Director Kenneth W. O'Keefe of Jazz Pharmaceuticals Plc surrendered 603 shares back to the company to cover option exercise costs and/or tax liabilities. The transaction was filed with the SEC on December 4, 2025, at a price of $173.07 per share, totaling $104,361. O'Keefe's ending holdings are 30,256 shares, with 25,811 direct and 4,445 indirect.

Reuters·
US
JAZZ
-0.11%
Reuters·
US
JAZZ
-0.11%

Jazz Pharmaceuticals Announces Positive Phase 3 Results for Ziihera in HER2-Positive Gastroesophageal Cancer

Jazz Pharmaceuticals announced positive Phase 3 results for Ziihera in HER2-positive gastroesophageal cancer. The study showed significant improvements in progression-free survival and overall survival with Ziihera combinations, compared to the control arm. Results will be presented at the 2026 ASCO GI Symposium.

Reuters·
US
JAZZ
-0.11%
Reuters·
US
JAZZ
-0.11%

Jazz Pharmaceuticals Insider Sold Shares Worth $13,780,337, According to a Recent SEC Filing

03:28 AM EST, 12/02/2025 (MT Newswires) -- Bruce C Cozadd, Director, on November 26, 2025, sold 77,500 shares in Jazz Pharmaceuticals ( JAZZ ) for $13,780,337. Following the Form 4 filing with the SEC, Cozadd has control over a total of 393,332 ordinary shares of the company, with 393,332 shares held directly.SEC Filing: MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

fidelity·
US
JAZZ
-0.11%
fidelity·
US
JAZZ
-0.11%

Dir O'Keefe Files To Sell 1,249 Of Jazz Pharmaceuticals Plc [JAZZ]

Director Kenneth W. O'Keefe of Jazz Pharmaceuticals Plc filed a Form 144 with the SEC to sell 1,249 shares on December 1, 2025. The sale is planned for December 2, 2025, through E-TRADE Financial. Form 144 is required for selling restricted stock within 90 days of filing.

Reuters·
US
JAZZ
-0.11%
Reuters·
US
JAZZ
-0.11%

Chmn Cozadd Sells 77,500 ($13.8M) Of Jazz Pharmaceuticals Plc [JAZZ]

Cozadd Bruce C Chairman of the Board of Jazz Pharmaceuticals Plc [JAZZ] filed a Form 4 on December 1, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:DateTransactionSharesPriceValue11/26/25Exercise(1) 77,500$123.36$9,560,40011/26/25Sale77,500$177.81$13,780,337Ending Holdings: 393,332 - Direct(1) Exercised 3.0 months before expiration date.For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Reuters·
US
JAZZ
-0.11%
Reuters·
US
JAZZ
-0.11%
© 2025 Longbridge｜Disclaimer